Triumvira Immunologics Establishes Scientific Advisory Board

AUSTIN, Texas & HAMILTON, Ontario--(BUSINESS WIRE)-- Triumvira Immunologics, Inc. (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that the company formed its inaugural Scientific Advisory Board (SAB), comprising four leading scientists and physicians. Jonathan Bramson, Ph.D., Scientific Co-Founder of Triumvira, Professor of Pathology and Molecular Medicine, and Vice Dean of Research at McMaster University, will serve as chair of the SAB.

“The esteemed group of cell therapy, oncology, molecular medicine, drug development and manufacturing experts we have assembled to serve on our Scientific Advisory Board will support Triumvira’s efforts as we further our preclinical and clinical research strategy and advance the development of our targeted TAC-T cell therapies to treat patients with solid tumors,” said Paul Lammers, M.D., M.Sc., President and CEO of Triumvira. “Having recently dosed the first patient in a clinical trial of TAC01-HER2, our clinical program is at an exciting inflection point and I believe that each member of our Scientific Advisory Board will serve Triumvira well as we strive to deliver new treatments to patients with difficult-to-treat cancers.”

“I’m honored to serve as chair of Triumvira’s Scientific Advisory Board alongside distinguished experts in our industry,” said Dr. Bramson. “Together, we look forward to guiding Triumvira through the development of its strong and broad pipeline that demonstrates the versatility of the TAC-T cell platform.”

The founding members of the Triumvira Scientific Advisory Board are:

Jonathan Bramson, Ph.D.

Dr. Bramson is the founder of Triumvira and chair of its Scientific Advisory Board. He is currently Professor of Pathology and Molecular Medicine and Vice Dean of Research at McMaster University, where he also holds a Tier 1 Canada Research Chair in Translational Cancer Immunology and the John Bienenstock Chair in Molecular Medicine. Dr. Bramson’s lab studies mechanisms by which the adaptive immune system recognizes and responds to tumors, with a focus on developing immunological strategies to fight cancer.

Malcolm Brenner, M.D., Ph.D.

Dr. Brenner has devoted his career as a physician-scientist to the field of stem cell transplantation through the therapeutic use of T cell immunologic approaches and genetic engineering strategies. He is the founding director of the Center for Cell and Gene Therapy and the Fayez Sarofim Distinguished Service Professor at Baylor College of Medicine in the Departments of Medicine, Pediatrics, and Human and Molecular Genetics. He served as Editor-in-Chief of Molecular Therapy and as former President of the American Society for Gene and Cell Therapy (ASGCT) and of the International Society for Cell Therapy (ISCT).

John McMannis, Ph.D.

Dr. McMannis is Chief Operating Officer at Cellenkos, an early stage clinical biotechnology company that focuses on umbilical cord blood derived T-regulatory cellular therapies for treating autoimmune diseases and inflammatory disorders. He was previously Executive Vice President at Mesoblast, where he oversaw manufacturing operations for cellular products, and Professor at the University of Texas MD Anderson Cancer Center where he led the Cell Therapy Laboratory.

Michael Seiden, M.D., Ph.D.

Dr. Seiden served most recently as President of The US Oncology Network, a subsidiary of McKesson Corporation. He served as CEO, President and Cancer Center Director at the Fox Chase Cancer Center from 2007 to 2013. Previously, Dr. Seiden was Director in the Section of Clinical and Translational Research, Division of Cancer Biology at Massachusetts General Hospital.

For more information about Triumvira and its leadership team, visit www.triumvira.com.

About Triumvira Immunologics

Triumvira Immunologics, Inc. (“Triumvira”) is a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company’s proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. Triumvira is headquartered in Austin, Texas with research facilities in Hamilton, Ontario.

For more information, please visit www.triumvira.com or send email inquiries to partners@triumvira.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220118005558/en/